ACS Medicinal Chemistry Letters
Letter
(5)Lu, C.;Everhart, L.;Tilan, J.;Kuo, L.;Sun, C. C. J.;Munivenkatappa,
R. B.; Joensson-Rylander, A. C.; Sun, J.; Kuan-Celarier, A.; Li, L.; Abe, K.;
Zukowska, Z.; Toretsky, J. A.; Kitlinska, J. Neuropeptide Y and its Y2
receptor: potential targets in neuroblastoma therapy. Oncogene 2010, 29,
5630−5642.
(6) Morgat, C.; Mishra, A. K.; Varshney, R.; Allard, M.; Fernandez, P.;
Hindie, E. Targeting neuropeptide receptors for cancer imaging and
therapy: perspectives with bombesin, neurotensin, and neuropeptide-Y
receptors. J. Nucl. Med. 2014, 55, 1650−1657.
(7)Amlal, H.; Faroqui, S.;Balasubramaniam, A.;Sheriff, S. Estrogen up-
regulatesneuropeptideYY1 receptorexpressioninahumanbreastcancer
cell line. Cancer Res. 2006, 66, 3706−3714.
(8) Memminger, M.; Keller, M.; Lopuch, M.; Pop, N.; Bernhardt, G.;
von Angerer, E.; Buschauer, A. The neuropeptide Y Y1 receptor: a
diagnostic marker? Expression in MCF-7 breast cancer cells is down-
regulated by antiestrogens in vitro and in xenografts. PLoS One 2012, 7,
e51032.
highly potent and selective non-peptide neuropeptide Y Y1 receptor
antagonist: BIBP3226. Eur. J. Pharmacol. 1994, 271, R11−3.
(22) Schneider, E.; Keller, M.; Brennauer, A.; Hoefelschweiger, B. K.;
Gross, D.; Wolfbeis, O. S.; Bernhardt, G.; Buschauer, A. Synthesis and
characterization of the first fluorescent nonpeptide NPY Y1 receptor
antagonist. ChemBioChem 2007, 8, 1981−8.
(23) Keller, M.; Erdmann, D.; Pop, N.; Pluym, N.; Teng, S.; Bernhardt,
G.; Buschauer, A. Red-fluorescent argininamide-type NPY Y1 receptor
antagonists as pharmacological tools. Bioorg. Med. Chem. 2011, 19,
2859−2878.
(24) Weiss, S.; Keller, M.; Bernhardt, G.; Buschauer, A.; Koenig, B.
Modular synthesis of non-peptidic bivalent NPY Y1 receptor antagonists.
Bioorg. Med. Chem. 2008, 16, 9858−9866.
(25) Keller, M.; Teng, S.; Bernhardt, G.; Buschauer, A. Bivalent
Argininamide-Type Neuropeptide Y Y1 Antagonists Do Not Support the
Hypothesis of Receptor Dimerization. ChemMedChem 2009, 4, 1733−
1745.
(26) Keller, M.; Kaske, M.; Holzammer, T.; Bernhardt, G.; Buschauer,
A. Dimeric argininamide-type neuropeptide Y receptor antagonists:
chiral discrimination between Y1 and Y4 receptors. Bioorg. Med. Chem.
2013, 21, 6303−6322.
(9) Li, Z.; Conti, P. S. Radiopharmaceutical chemistry for positron
emission tomography. Adv. Drug Delivery Rev. 2010, 62, 1031−1051.
(10) Langer, M.; La Bella, R.; Garcia-Garayoa, E.; Beck-Sickinger, A. G.
99mTc-Labeled Neuropeptide Y Analogues as Potential Tumor Imaging
Agents. Bioconjugate Chem. 2001, 12, 1028−1034.
(11) Zwanziger, D.; Khan, I. U.; Neundorf, I.; Sieger, S.; Lehmann, L.;
Friebe, M.; Dinkelborg, L.; Beck-Sickinger, A. G. Novel chemically
modified analogues of neuropeptide Y for tumor targeting. Bioconjugate
Chem. 2008, 19, 1430−8.
(12) Khan, I. U.; Beck-Sickinger, A. G. Targeted tumor diagnosis and
therapy with peptide hormones as radiopharmaceuticals. Anti-Cancer
Agents Med. Chem. 2008, 8, 186−99.
(13) Khan, I. U.; Zwanziger, D.; Bohme, I.; Javed, M.; Naseer, H.;
Hyder, S. W.; Beck-Sickinger, A. G. Breast-cancer diagnosis by
neuropeptide Y analogues: from synthesis to clinical application.
Angew. Chem., Int. Ed. 2010, 49, 1155−8.
(14) Guerin, B.; Dumulon-Perreault, V.; Tremblay, M.-C.; Ait-
Mohand, S.; Fournier, P.; Dubuc, C.; Authier, S.; Benard, F.
[Lys(DOTA)4]BVD15, a novel and potent neuropeptide Y analog
designed for Y1 receptor-targeted breast tumor imaging. Bioorg. Med.
Chem. Lett. 2010, 20, 950−953.
(15) Chatenet, D.; Cescato, R.; Waser, B.; Erchegyi, J.; Rivier, J. E.;
Reubi, J. C. Novel dimeric DOTA-coupled peptidic Y1-receptor
antagonists for targeting of neuropeptide Y receptor-expressing cancers.
EJNMMI Res. 2011, 1, 21.
(16) Kameda, M.; Ando, M.; Nakama, C.; Kobayashi, K.; Kawamoto,
H.; Ito, S.; Suzuki, T.; Tani, T.; Ozaki, S.; Tokita, S.; Sato, N. Synthesis
and evaluation of a series of 2,4-diaminopyridine derivatives as potential
positron emission tomography tracers for neuropeptide Y Y1 receptors.
Bioorg. Med. Chem. Lett. 2009, 19, 5124−5127.
(27) Keller, M.; Pop, N.; Hutzler, C.; Beck-Sickinger, A. G.; Bernhardt,
G.; Buschauer, A. Guanidine-Acylguanidine Bioisosteric Approach in the
Design of Radioligands: Synthesis of a Tritium-Labeled NG-Propiony-
largininamide ([3H]-UR-MK114) as a Highly Potent and Selective
Neuropeptide Y Y1 Receptor Antagonist. J. Med. Chem. 2008, 51, 8168−
8172.
(28) Keller, M.; Bernhardt, G.; Buschauer, A. [3H]UR-MK136: A
Highly Potent and Selective Radioligand for Neuropeptide Y Y1
Receptors. ChemMedChem 2011, 6, 1566−1571.
(29) Keller, M.; Weiss, S.; Hutzler, C.; Kuhn, K. K.; Mollereau, C.;
Dukorn, S.; Schindler, L.; Bernhardt, G.; Koenig, B.; Buschauer, A. Nω-
Carbamoylation of the argininamide moiety: an avenue to insurmount-
able NPY Y1 receptor antagonists and a radiolabeled selective high-
affinity molecular tool ([3H]UR-MK299) with extended residence time.
J. Med. Chem. 2015, 58, 8834−8849.
(30) Pluym, N.; Brennauer, A.; Keller, M.; Ziemek, R.; Pop, N.;
Bernhardt, G.; Buschauer, A. Application of the Guanidine-Acylguani-
dine Bioisosteric Approach to Argininamide-Type NPY Y2 Receptor
Antagonists. ChemMedChem 2011, 6, 1727−1738.
(31) Pluym, N.;Baumeister, P.;Keller, M.;Bernhardt, G.;Buschauer, A.
[3H]UR-PLN196: a selective nonpeptide radioligand and insurmount-
able antagonist for the neuropeptide Y Y2 receptor. ChemMedChem
2013, 8, 587−593.
(32) Keller, M.; Kuhn, K. K.; Einsiedel, J.; Huebner, H.; Biselli, S.;
Mollereau, C.; Wifling, D.; Svobodova, J.; Bernhardt, G.; Cabrele, C.;
Vanderheyden, P. M. L.; Gmeiner, P.; Buschauer, A. Mimicking of
Arginine by Functionalized Nω-Carbamoylated Arginine As a New
Broadly Applicable Approach to Labeled Bioactive Peptides: High
Affinity Angiotensin, Neuropeptide Y, Neuropeptide FF, and Neuro-
tensin Receptor Ligands As Examples. J. Med. Chem. 2016, 59, 1925−
1945.
(17) Hostetler, E. D.; Sanabria-Bohorquez, S.; Fan, H.; Zeng, Z.;
Gantert, L.;Williams, M.;Miller, P.;O’Malley, S.;Kameda, M.;Ando, M.;
Sato, N.; Ozaki, S.; Tokita, S.; Ohta, H.; Williams, D.; Sur, C.; Cook, J. J.;
Burns, H. D.; Hargreaves, R. Synthesis, characterization, and monkey
positron emission tomography (PET) studies of [18F]Y1−973, a PET
tracer for the neuropeptide Y Y1 receptor. NeuroImage 2011, 54, 2635−
2642.
(33) Maschauer, S.; Prante, O. A series of 2-O-trifluoromethylsulfonyl-
D-mannopyranosides as precursors for concomitant 18F-labeling and
glycosylation by click chemistry. Carbohydr. Res. 2009, 344, 753−761.
(18) Hofmann, S.; Maschauer, S.; Kuwert, T.; Beck-Sickinger, A. G.;
Prante, O. Synthesis and in Vitro and in Vivo Evaluation of an 18F-
Labeled Neuropeptide Y Analogue for Imaging of Breast Cancer by PET.
Mol. Pharmaceutics 2015, 12, 1121−1130.
(34) Muller, M.; Knieps, S.; Gessele, K.; Dove, S.; Bernhardt, G.;
̈
Buschauer, A. Synthesis and neuropeptide Y Y1 receptor antagonistic
activity of N,N-disubstituted omega-guanidino- and omega-amino-
alkanoic acid amides. Arch. Pharm. 1997, 330, 333−42.
(19) Lang, C.; Maschauer, S.; Hubner, H.; Gmeiner, P.; Prante, O.
̈
(35) Wester, H.-J.; Hamacher, K.; Stocklin, G. A comparative study of
̈
Synthesis and evaluation of a 18F-labeled diarylpyrazole glycoconjugate
for the imaging of NTS1-positive tumors. J. Med. Chem. 2013, 56, 9361−
9365.
n.c.a. fluorine-18 labeling of proteins via acylation and photochemical
conjugation. Nucl. Med. Biol. 1996, 23, 365−372.
(36) Okamoto, M.;Naka, K.;Kitagawa, Y.; Ishiwata, K.;Yoshimoto, M.;
Shimizu, I.; Toyohara, J. Synthesis and evaluation of 7alpha-(3-
[18F]fluoropropyl) estradiol. Nucl. Med. Biol. 2015, 42, 590−7.
(37) Kuchar, M.; Mamat, C. Methods to Increase the Metabolic
Stability of 18F-Radiotracers. Molecules 2015, 20, 16186−220.
(20) Schulz, J.; Rohracker, M.; Stiebler, M.; Grosser, O. S.; Pethe, A.;
Goldschmidt, J.; Osterkamp, F.; Reineke, U.; Smerling, C.; Amthauer, H.
Comparative Evaluation of the Biodistribution Profiles of a Series of
Nonpeptidic Neurotensin Receptor-1 Antagonists Reveals a Promising
Candidate for Theranostic Applications. J. Nucl. Med. 2016, 57, 1120−3.
(21) Rudolf, K.; Eberlein, W.; Engel, W.; Wieland, H. A.; Willim, K. D.;
Entzeroth, M.;Wienen, W.;Beck-Sickinger, A. G.;Doods, H. N. Thefirst
F
ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX